StreetInsider.com News Articles

Form 8-K TELEFLEX INC For: Jun 15

Mon, 15 Jun 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260615/26648694.html

Form 8-K TELEFLEX INC For: Jun 15

Mon, 15 Jun 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260615/26648694.html

Form 4 TELEFLEX INC For: Jun 07 Filed by: RANDLE STUART A

Tue, 09 Jun 2026 20:33:00 -0400

si-local-file:///var/storage/secattach/20260609/26625273.html

Form 4 TELEFLEX INC For: Jun 07 Filed by: RANDLE STUART A

Tue, 09 Jun 2026 20:33:00 -0400

si-local-file:///var/storage/secattach/20260609/26625273.html

Form 3 TELEFLEX INC For: Jun 08 Filed by: Weidman Jason R.

Tue, 09 Jun 2026 20:31:00 -0400

si-local-file:///var/storage/secattach/20260609/26625270.html

Form 3 TELEFLEX INC For: Jun 08 Filed by: Weidman Jason R.

Tue, 09 Jun 2026 20:31:00 -0400

si-local-file:///var/storage/secattach/20260609/26625270.html

Form 4 TELEFLEX INC For: Jun 08 Filed by: Weidman Jason R.

Tue, 09 Jun 2026 20:31:00 -0400

si-local-file:///var/storage/secattach/20260609/26625272.html

Form 4 TELEFLEX INC For: Jun 08 Filed by: Weidman Jason R.

Tue, 09 Jun 2026 20:31:00 -0400

si-local-file:///var/storage/secattach/20260609/26625272.html

Form 8-K TELEFLEX INC For: Jun 08

Tue, 09 Jun 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260609/26624747.html

Form 8-K TELEFLEX INC For: Jun 08

Tue, 09 Jun 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260609/26624747.html

Teleflex reports four-year study data on resorbable heart scaffold

Tue, 09 Jun 2026 06:30:54 -0400

Teleflex Incorporated (NYSE: TFX) announced four-year follow-up results from its BIOMAG-I clinical study of the Freesolve Resorbable Magnesium Scaffold at the EuroPCR conference in Paris. The study, which enrolled 116 patients across European centers, showed no new cardiac-related events between the two and four-year follow-up periods.

The data presented by Prof. Jan Torzewski from Klinikverbund Allgäu, Germany, indicated no cardiac deaths, target-vessel myocardial infarctions, or scaffold thrombosis through four years. The target lesion failure rate was 3.5%, with only one event occurring beyond the scaffold's one-year resorption period.

"The absence of cardiac death, target-vessel MI, or scaffold thrombosis throughout four years, combined

Four‑Year BIOMAG™-I Study Results Presented at EuroPCR Confirm Long‑Term Safety and Sustained Performance of the Freesolve™ Resorbable Magnesium Scaffold (DREAMS 3G)

Tue, 09 Jun 2026 06:30:00 -0400

Persistently Low Target Lesion Failure and No New Cardiac-Related Event

WAYNE, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the four‑year follow‑up data from the First-in-Human BIOMAG™-I Clinical Study (NCT04157153)* presented at the EuroPCR conference in Paris, France by Prof. Jan Torzewski (Klinikverbund Allgäu, Germany).

Conducted exclusively across European centers and enrolling 116 patients, the study continues to demonstrate a favorable long‑term safety profile1, with no new cardiac‑related1 events observed between two and four years follow‑up period, establishing the third-generation Freesolve™ Resorbable Magnesium Scaffold (RMS) as a valuable treatment option.

Prof. Torzewski

Four‑Year BIOMAG™-I Study Results Presented at EuroPCR Confirm Long‑Term Safety and Sustained Performance of the Freesolve™ Resorbable Magnesium Scaffold (DREAMS 3G)

Tue, 09 Jun 2026 06:30:00 -0400

Persistently Low Target Lesion Failure and No New Cardiac-Related Event

Prof. Torzewski

Four‑Year BIOMAG™-I Study Results Presented at EuroPCR Confirm Long‑Term Safety and Sustained Performance of the Freesolve™ Resorbable Magnesium Scaffold (DREAMS 3G)

Tue, 09 Jun 2026 06:30:00 -0400

Persistently Low Target Lesion Failure and No New Cardiac-Related Event

Prof. Torzewski

Four‑Year BIOMAG™-I Study Results Presented at EuroPCR Confirm Long‑Term Safety and Sustained Performance of the Freesolve™ Resorbable Magnesium Scaffold (DREAMS 3G)

Tue, 09 Jun 2026 06:30:00 -0400

Persistently Low Target Lesion Failure and No New Cardiac-Related Event

Prof. Torzewski

Piper Sandler Assumes Coverage and Upgrades Teleflex (TFX) to Overweight

Mon, 08 Jun 2026 04:00:57 -0400

Piper Sandler analyst Jason Bednar upgraded Teleflex (NYSE: TFX) from Neutral to Overweight with a price target of $160.00 (from $140.00).

The analyst comments: “We’re transferring coverage of Teleflex to Jason Bednar, and upgrading the shares to OW with a $160 PT. Inexpensive medtech stocks haven't been compelling investment ideas ytd, but our upgrade is tied to upside we see for TFX that could materialize through several forms - fundamentally through Biotronik synergies, upward estimate revisions once Street models fully reflect capital deployment, and/or value creation via activist involvement. Even FreeSolve-related catalysts could begin helping the narrative as soon as '27

Piper Sandler Assumes Coverage and Upgrades Teleflex (TFX) to Overweight

Mon, 08 Jun 2026 04:00:57 -0400

Piper Sandler analyst Jason Bednar upgraded Teleflex (NYSE: TFX) from Neutral to Overweight with a price target of $160.00 (from $140.00).

Form 8-K TELEFLEX INC For: Jun 01

Tue, 02 Jun 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260602/26586632.html

Form 8-K TELEFLEX INC For: Jun 01

Tue, 02 Jun 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260602/26586632.html

Teleflex prices $500 million senior notes offering at 5.875%

Mon, 01 Jun 2026 17:40:12 -0400

Teleflex Incorporated (NYSE: TFX) announced it priced a private offering of $500 million in senior notes due 2032 at a 5.875% interest rate and an issue price of 100.000%.

The Wayne, Pennsylvania-based medical technology company expects the sale to close on June 15, 2026, subject to customary closing conditions. The notes will be guaranteed by Teleflex's existing and future wholly-owned domestic subsidiaries that serve as guarantors under its credit agreement.

Teleflex plans to use the net proceeds from the offering, along with cash on hand, to redeem all outstanding 4.625% Senior Notes due 2027.

The offering will be conducted as a private transaction

Teleflex prices $500 million senior notes offering at 5.875%

Mon, 01 Jun 2026 17:40:12 -0400

Teleflex Incorporated (NYSE: TFX) announced it priced a private offering of $500 million in senior notes due 2032 at a 5.875% interest rate and an issue price of 100.000%.

Teleflex plans to use the net proceeds from the offering, along with cash on hand, to redeem all outstanding 4.625% Senior Notes due 2027.

The offering will be conducted as a private transaction

Teleflex Incorporated Announces Pricing of $500 Million Senior Notes Offering

Mon, 01 Jun 2026 17:40:00 -0400

WAYNE, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYSE: TFX) (“Teleflex”) announced today that it priced its private offering of $500.0 million aggregate principal amount of 5.875% senior notes due 2032 (the “Notes”) at an issue price of 100.000%. The sale of the Notes is expected to close on June 15, 2026, subject to customary closing conditions.

The Notes will be guaranteed by each of Teleflex’s existing and future wholly-owned domestic subsidiaries that is a guarantor or other obligor under its credit agreement and certain other indebtedness.

Teleflex intends to use the net proceeds from the offering, together with cash on hand,

Teleflex Incorporated Announces Pricing of $500 Million Senior Notes Offering

Mon, 01 Jun 2026 17:40:00 -0400

Teleflex intends to use the net proceeds from the offering, together with cash on hand,

Teleflex Incorporated Announces Pricing of $500 Million Senior Notes Offering

Mon, 01 Jun 2026 17:40:00 -0400

Teleflex intends to use the net proceeds from the offering, together with cash on hand,

Teleflex Incorporated Announces Pricing of $500 Million Senior Notes Offering

Mon, 01 Jun 2026 17:40:00 -0400

Teleflex intends to use the net proceeds from the offering, together with cash on hand,